Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
vTv Therapeutics Inc. reported preliminary financial results for fiscal year ended December 31, 2023.
- Period
- fiscal year ended December 31, 2023
- Result
- preliminary results
Exact text from the filing
Preliminary Financial Results - Cash Balance as of December 31, 2023 Based upon preliminary estimates and information available to the Company, it expects to report that it had cash and cash equivalents of approximately $9.4 million as of December 31, 2023.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
vTv Therapeutics Inc. entered into Sales Agreement with Cowen and Company, LLC valued at up to $50.0 million (effective 2024-02-28).
- Action
- entry
- Agreement
- atm program
- Counterparty
- Cowen and Company, LLC
- Value
- up to $50.0 million
- Effective
- 2024-02-28
Exact text from the filing
On February 28, 2024, vTv Therapeutics Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC (“TD Cowen”), pursuant to which the Company may offer and sell, from time to time, through TD Cowen, as sales agent, shares of the Company’s Class A common stock, par value $0.01 per share, having an aggregate offering price of up to $50.0 million (the “ATM Offering”).
View on SEC.gov